412 related items for PubMed ID: 17870094
1.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
2. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ.
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[Abstract] [Full Text] [Related]
3. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ, Figgitt DP.
CNS Drugs; 2004 Apr; 18(6):379-96. PubMed ID: 15089110
[Abstract] [Full Text] [Related]
4. Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis.
Perini P, Gallo P.
J Neurol; 2003 Jul; 250(7):834-8. PubMed ID: 12883926
[Abstract] [Full Text] [Related]
5. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.
Debouverie M, Taillandier L, Pittion-Vouyovitch S, Louis S, Vespignani H.
Mult Scler; 2007 Jun; 13(5):626-31. PubMed ID: 17548442
[Abstract] [Full Text] [Related]
6. [Mitoxantrone].
Pericot I, Montalban X.
Neurologia; 2003 Jun; 18(6):318-23. PubMed ID: 12838451
[Abstract] [Full Text] [Related]
7. Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status.
Ostberg A, Pittas F, Taylor B.
Intern Med J; 2005 Jul; 35(7):382-7. PubMed ID: 15958106
[Abstract] [Full Text] [Related]
8. Predictors of relapse rate in MS clinical trials.
Held U, Heigenhauser L, Shang C, Kappos L, Polman C, Sylvia Lawry Centre for MS Research.
Neurology; 2005 Dec 13; 65(11):1769-73. PubMed ID: 16344520
[Abstract] [Full Text] [Related]
9. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Campagnolo D, Deutsch F, Arnold DL.
Mult Scler; 2008 Jun 13; 14(5):663-70. PubMed ID: 18424479
[Abstract] [Full Text] [Related]
10.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
12. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
Krapf H, Morrissey SP, Zenker O, Zwingers T, Gonsette R, Hartung HP, MIMS Study Group.
Neurology; 2005 Sep 13; 65(5):690-5. PubMed ID: 16157900
[Abstract] [Full Text] [Related]
13. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
Clin Ther; 2008 Jun 13; 30(6):1102-12. PubMed ID: 18640466
[Abstract] [Full Text] [Related]
14. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
van de Wyngaert FA, Beguin C, D'Hooghe MB, Dooms G, Lissoir F, Carton H, Sindic CJ.
Acta Neurol Belg; 2001 Dec 13; 101(4):210-6. PubMed ID: 11851027
[Abstract] [Full Text] [Related]
15. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
Patti F, Amato MP, Filippi M, Gallo P, Trojano M, Comi GC.
J Neurol Sci; 2004 Aug 15; 223(1):69-71. PubMed ID: 15261564
[Abstract] [Full Text] [Related]
16. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
Pascual AM, Téllez N, Boscá I, Mallada J, Belenguer A, Abellán I, Sempere AP, Fernández P, Magraner MJ, Coret F, Sanz MA, Montalbán X, Casanova B.
Mult Scler; 2009 Nov 15; 15(11):1303-10. PubMed ID: 19825889
[Abstract] [Full Text] [Related]
17. [Mitoxantrone for the treatment of Japanese patients with multiple sclerosis].
Komori M, Tanaka M, Muramoto E, Ohno M, Matsumoto R, Murase N, Kitagawa N, Saida T.
Rinsho Shinkeigaku; 2007 Jul 15; 47(7):401-6. PubMed ID: 17710882
[Abstract] [Full Text] [Related]
18. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).
Weinstock-Guttman B, Ramanathan M, Lincoff N, Napoli SQ, Sharma J, Feichter J, Bakshi R.
Arch Neurol; 2006 Jul 15; 63(7):957-63. PubMed ID: 16831964
[Abstract] [Full Text] [Related]
19.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
20. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis.
Cocco E, Marchi P, Sardu C, Russo P, Paolillo A, Mascia M, Solla M, Frau J, Lorefice L, Massole S, Floris G, Marrosu M.
Mult Scler; 2007 Sep 15; 13(8):975-80. PubMed ID: 17468439
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
